The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni ...
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...
The FDA granted accelerated approval to lunsotogene parvec (Otarmeni) as the first gene therapy for genetic hearing loss, the ...
The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...
The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...
Formerly known as DB-OTO, lunsotogene parvec is an adeno-associated virus (AAV) vector–based gene therapy administered via a ...
Turkey’s trajectory is not dependent on the outcome of the Iranian case - it is a function of its desire to claim leadership ...
Jean-Marc Chery said Q1 net revenues were $3.1 billion and highlighted that “we had a strong booking momentum during Q1 with book-to-bill well above 1 across all end markets and regions.” CEO Chery ...
Travis Smith was a very serious baby. Born completely unable to hear, his mother Sierra struggled to see his personality ...
According to MarketsandMarkets, "Aliphatic Hydrocarbon Solvents and Thinners Market by Type (Varnish Makers' & Painters' ...
Morning Overview on MSN
Gene therapy restored hearing in 90% with OTOF deafness, study says
A single injection into the inner ear restored functional hearing in 90% of people born deaf because of mutations in the OTOF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results